Product Information
ERYTHROMYCIN 0.5% EYE OINTMENT is a generic product labeled by Bausch & Lomb Incorporated, priced at $6.8340 per GM under NDC 24208091019. Its NADAC has been published 234 times since May 17, 2017.
FDA first approved this application on Jul 29, 1994. Its Orange Book therapeutic-equivalence code is AT.
Strength
5 mg/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208091019
Classification
Generic
Dosage Form
OINTMENT
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA064067FDA Approved
7/29/1994
TE Code
AT
On Market Since
7/29/1994
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 0.5% EYE OINTMENT has been published 234 times since May 17, 2017, and over the history we have for it it has declined 3.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.8340 per GM |
|---|---|
| All-time high | $7.6426 (Sep 10, 2025) |
| All-time low | $3.4370 (May 22, 2024) |
| 52-week high | $7.2287 |
| 52-week low | $6.1653 |
| Median price | $6.3254 |
| Average price | $5.8952 |
| Largest weekly change | -32.8% (Apr 17, 2024) |
| Weeks tracked | 234 |
| Tracking since | May 17, 2017 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 59% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 0.5% EYE OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 0.5% EYE OINTMENT, manufactured by Bausch & Lomb Incorporated, is $6.8340 per GM (NDC 24208091019), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 0.5% EYE OINTMENT changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 0.5% EYE OINTMENT has declined 3.8%. It has been tracked across 234 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 0.5% EYE OINTMENT?
Since May 17, 2017, the NADAC for ERYTHROMYCIN 0.5% EYE OINTMENT has ranged from a low of $3.4370 (May 22, 2024) to a high of $7.6426 (Sep 10, 2025), with a median of $6.3254 per GM.
Are there cheaper alternatives to ERYTHROMYCIN 0.5% EYE OINTMENT?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERYTHROMYCIN 0.5% EYE OINTMENT, is $2.8266 per GM — about 59% below ERYTHROMYCIN 0.5% EYE OINTMENT.
Who manufactures ERYTHROMYCIN 0.5% EYE OINTMENT?
ERYTHROMYCIN 0.5% EYE OINTMENT (NDC 24208091019) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.